{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:01:55Z","timestamp":1791478915840,"version":"4.3.4"},"reference-count":176,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"Abstract<\/jats:title>\n Background<\/jats:title>\n Alzheimer\u2019s disease (AD) is a common, complex and multifactorial disease that may require screening across multiple routes of referral to enable early detection and subsequent future implementation of tailored interventions. Blood- and eye-based biomarkers show promise as low-cost, scalable and patient-friendly tools for early AD detection given their ability to provide information on AD pathophysiological changes and manifestations in the retina, respectively. Eye clinics provide an intriguing real-world proof-of-concept setting to evaluate the performance of these potential AD screening tools given the intricate connections between the eye and brain, presumed enrichment for AD pathology in the aging population with eye disorders, and the potential for an accelerated diagnostic pathway for under-recognized patient groups.<\/jats:p>\n <\/jats:sec>\n Methods<\/jats:title>\n The BeyeOMARKER study is a prospective, observational, longitudinal cohort study aiming to include individuals visiting an eye-clinic. Inclusion criteria entail being\u2009\u2265\u200950 years old and having no prior dementia diagnosis. Excluded eye-conditions include traumatic insults, superficial inflammation, and conditions in surrounding structures of the eye that are not engaged in vision. The BeyeOMARKER cohort (n<\/jats:italic>\u2009=\u2009700) will undergo blood collection to assess plasma p-tau217 levels and a brief cognitive screening at the eye clinic. All participants will subsequently be invited for annual longitudinal follow-up including remotely administered cognitive screening and questionnaires. The BeyeOMARKER\u2009+\u2009cohort (n<\/jats:italic>\u2009=\u2009150), consisting of 100 plasma p-tau217 positive participants and 50 matched negative controls selected from the BeyeOMARKER cohort, will additionally undergo A\u03b2-PET and tau-PET, MRI, retinal imaging including hyperspectral imaging (primary), widefield imaging, optical coherence tomography (OCT) and OCT-Angiography (secondary), and cognitive and cortical vision assessments.<\/jats:p>\n <\/jats:sec>\n Results<\/jats:title>\n We aim to implement the current protocol between April 2024 until March 2027. Primary outcomes include the performance of plasma p-tau217 and hyperspectral retinal imaging to detect AD pathology (using A\u03b2- and tau-PET visual read as reference standard) and to detect cognitive decline. Initial follow-up is\u2009~\u20092\u00a0years but may be extended with additional funding.<\/jats:p>\n <\/jats:sec>\n Conclusions<\/jats:title>\n We envision that the BeyeOMARKER study will demonstrate the feasibility of early AD detection based on blood- and eye-based biomarkers in alternative screening settings, and will improve our understanding of the eye-brain connection.<\/jats:p>\n <\/jats:sec>\n Trial registration<\/jats:title>\n The BeyeOMARKER study (Eudamed CIV ID: CIV-NL-23\u201309-044086; registration date: 19th of March 2024) is approved by the ethical review board of the Amsterdam UMC.<\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s13195-024-01545-1","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T08:23:31Z","timestamp":1724401411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer\u2019s disease pathology in the eye clinic"],"prefix":"10.1186","volume":"16","author":[{"given":"Ilse","family":"Bader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Stevie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie A.","family":"Milongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurre den","family":"Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M. W.","family":"Verberk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keir","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Orellina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argonde C.","family":"van Harten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline H. B.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande A. L.","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsmarieke","family":"van de Giessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke H.","family":"Bouwman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"issue":"4","key":"1545_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1545_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1545_CR3","first-page":"371","volume":"8","author":"AP Porsteinsson","year":"2021","unstructured":"Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of Early Alzheimer\u2019s Disease: Clinical Practice in 2021. J Prev Alzheimers Dis. 2021;8(3):371\u201386.","journal-title":"J Prev Alzheimers Dis"},{"issue":"7","key":"1545_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41582-022-00645-6","volume":"18","author":"PS Aisen","year":"2022","unstructured":"Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R. Early-stage Alzheimer disease: getting trial-ready. Nat Rev Neurol. 2022;18(7):389\u201399.","journal-title":"Nat Rev Neurol."},{"key":"1545_CR5","first-page":"123","volume":"9","author":"J Rasmussen","year":"2019","unstructured":"Rasmussen J, Langerman H. Alzheimer\u2019s Disease - Why We Need Early Diagnosis. Degener Neurol Neuro. 2019;9:123\u201330.","journal-title":"Degener Neurol Neuro"},{"issue":"5","key":"1545_CR6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s43587-023-00404-2","volume":"3","author":"WM van der Flier","year":"2023","unstructured":"van der Flier WM, de Vugt ME, Smets EMA, Blom M, Teunissen CE. Towards a future where Alzheimer\u2019s disease pathology is stopped before the onset of dementia. Nature Aging. 2023;3(5):494\u2013505.","journal-title":"Nature Aging"},{"issue":"2","key":"1545_CR7","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"1545_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"1545_CR9","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"issue":"1","key":"1545_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41398-022-02237-w","volume":"12","author":"R Whelan","year":"2022","unstructured":"Whelan R, Barbey FM, Cominetti MR, Gillan CM, Rosicka AM. Developments in scalable strategies for detecting early markers of cognitive decline. Transl Psychiatry. 2022;12(1):473.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"1545_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40035-022-00296-z","volume":"11","author":"TO Klyucherev","year":"2022","unstructured":"Klyucherev TO, Olszewski P, Shalimova AA, Chubarev VN, Tarasov VV, Attwood MM, et al. Advances in the development of new biomarkers for Alzheimer\u2019s disease. Transl Neurodegener. 2022;11(1):25.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"1545_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66\u201377.","journal-title":"Lancet Neurol"},{"issue":"12","key":"1545_CR13","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2022;18(12):2669\u201386.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1545_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/alz.12006","volume":"16","author":"J Alber","year":"2020","unstructured":"Alber J, Goldfarb D, Thompson LI, Arthur E, Hernandez K, Cheng D, et al. Developing retinal biomarkers for the earliest stages of Alzheimer\u2019s disease: What we know, what we don\u2019t, and how to move forward. Alzheimers Dement. 2020;16(1):229\u201343.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1545_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/alz.12179","volume":"17","author":"PJ Snyder","year":"2021","unstructured":"Snyder PJ, Alber J, Alt C, Bain LJ, Bouma BE, Bouwman FH, et al. Retinal imaging in Alzheimer\u2019s and neurodegenerative diseases. Alzheimers & Dementia. 2021;17(1):103\u201311.","journal-title":"Alzheimers & Dementia"},{"issue":"1","key":"1545_CR16","first-page":"e12119","volume":"12","author":"J Alber","year":"2020","unstructured":"Alber J, Arthur E, Sinoff S, DeBuc DC, Chew EY, Douquette L, et al. A recommended \u201cminimum data set\u201d framework for SD-OCT retinal image acquisition and analysis from the Atlas of Retinal Imaging in Alzheimer\u2019s Study (ARIAS). Alzh Dement-Dadm. 2020;12(1):e12119.","journal-title":"Alzh Dement-Dadm."},{"issue":"4","key":"1545_CR17","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1016\/S2214-109X(21)00031-0","volume":"9","author":"BK Swenor","year":"2021","unstructured":"Swenor BK, Ehrlich JR. Ageing and vision loss: looking to the future. Lancet Glob Health. 2021;9(4):e385\u20136.","journal-title":"Lancet Glob Health"},{"issue":"7","key":"1545_CR18","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/jamaophthalmol.2016.1284","volume":"134","author":"R Varma","year":"2016","unstructured":"Varma R, Vajaranant TS, Burkemper B, Wu S, Torres M, Hsu C, et al. Visual Impairment and Blindness in Adults in the United States: Demographic and Geographic Variations From 2015 to 2050. JAMA Ophthalmol. 2016;134(7):802\u20139.","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"1545_CR19","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamaophthalmol.2021.0527","volume":"139","author":"AD Flaxman","year":"2021","unstructured":"Flaxman AD, Wittenborn JS, Robalik T, Gulia R, Gerzoff RB, Lundeen EA, et al. Prevalence of Visual Acuity Loss or Blindness in the US: A Bayesian Meta-analysis. JAMA Ophthalmology. 2021;139(7):717\u201323.","journal-title":"JAMA Ophthalmology"},{"issue":"6","key":"1545_CR20","first-page":"1347","volume":"80","author":"CR Jack","year":"2014","unstructured":"Jack CR. Biomarker Modeling of Alzheimer \u2019 s Disease. 2014;80(6):1347\u201358.","journal-title":"Biomarker Modeling of Alzheimer ' s Disease"},{"issue":"6","key":"1545_CR21","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","volume":"80","author":"CR Jack","year":"2013","unstructured":"Jack CR, Holtzman DM. Biomarker modeling of Alzheimer\u2019s disease. Neuron. 2013;80(6):1347\u201358.","journal-title":"Neuron"},{"issue":"2","key":"1545_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1545_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack","year":"2010","unstructured":"Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9(1):119\u201328.","journal-title":"Lancet Neurol"},{"issue":"17","key":"1545_CR24","doi-asserted-by":"publisher","first-page":"e1635","DOI":"10.1212\/WNL.0000000000008361","volume":"93","author":"D Altomare","year":"2019","unstructured":"Altomare D, de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, et al. Applying the ATN scheme in a memory clinic population: The ABIDE project. Neurology. 2019;93(17):e1635\u201346.","journal-title":"Neurology"},{"key":"1545_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.dadm.2016.09.002","volume":"6","author":"JE Baker","year":"2017","unstructured":"Baker JE, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL, Maruff P. Cognitive impairment and decline in cognitively normal older adults with high amyloid-\u03b2: A meta-analysis. Alzheimer\u2019s & dementia (Amsterdam, Netherlands). 2017;6:108\u201321.","journal-title":"Alzheimer's & dementia (Amsterdam, Netherlands)"},{"issue":"3","key":"1545_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMoa0809437","volume":"361","author":"RJ Caselli","year":"2009","unstructured":"Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med. 2009;361(3):255\u201363.","journal-title":"N Engl J Med"},{"issue":"15","key":"1545_CR27","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1038\/s41433-023-02481-4","volume":"37","author":"Y Xu","year":"2023","unstructured":"Xu Y, Phu J, Aung HL, Hesam-Shariati N, Keay L, Tully PJ, et al. Frequency of coexistent eye diseases and cognitive impairment or dementia: a systematic review and meta-analysis. Eye. 2023;37(15):3128\u201336.","journal-title":"Eye"},{"issue":"3","key":"1545_CR28","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3233\/JAD-210250","volume":"83","author":"E Kuzma","year":"2021","unstructured":"Kuzma E, Littlejohns TJ, Khawaja AP, Llewellyn DJ, Ukoumunne OC, Thiem U. Visual Impairment, Eye Diseases, and Dementia Risk: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2021;83(3):1073\u201387.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"1545_CR29","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/gerona\/glab325","volume":"77","author":"TJ Littlejohns","year":"2022","unstructured":"Littlejohns TJ, Hayat S, Luben R, Brayne C, Conroy M, Foster PJ, et al. Visual Impairment and Risk of Dementia in 2 Population-Based Prospective Cohorts: UK Biobank and EPIC-Norfolk. J Gerontol A Biol Sci Med Sci. 2022;77(4):697\u2013704.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"1545_CR30","doi-asserted-by":"publisher","first-page":"9109","DOI":"10.1038\/s41598-020-66002-z","volume":"10","author":"JS Paik","year":"2020","unstructured":"Paik JS, Ha M, Jung YH, Kim GH, Han KD, Kim HS, et al. Low vision and the risk of dementia: a nationwide population-based cohort study. Sci Rep. 2020;10(1):9109.","journal-title":"Sci Rep"},{"issue":"1","key":"1545_CR31","doi-asserted-by":"publisher","first-page":"e047929","DOI":"10.1136\/bmjopen-2020-047929","volume":"12","author":"N Nagarajan","year":"2022","unstructured":"Nagarajan N, Assi L, Varadaraj V, Motaghi M, Sun Y, Couser E, et al. Vision impairment and cognitive decline among older adults: a systematic review. BMJ Open. 2022;12(1):e047929.","journal-title":"BMJ Open."},{"issue":"1","key":"1545_CR32","first-page":"e12054","volume":"12","author":"PH Hwang","year":"2020","unstructured":"Hwang PH, Longstreth WT Jr, Brenowitz WD, Thielke SM, Lopez OL, Francis CE, et al. Dual sensory impairment in older adults and risk of dementia from the GEM Study. Alzheimers Dement (Amst). 2020;12(1):e12054.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1545_CR33","doi-asserted-by":"publisher","first-page":"872967","DOI":"10.3389\/fnagi.2022.872967","volume":"14","author":"W Hu","year":"2022","unstructured":"Hu W, Wang Y, Wang W, Zhang X, Shang X, Liao H, et al. Association of Visual, Hearing, and Dual Sensory Impairment With Incident Dementia. Front Aging Neurosci. 2022;14:872967.","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"1545_CR34","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ophtha.2020.12.029","volume":"128","author":"X Shang","year":"2021","unstructured":"Shang X, Zhu Z, Wang W, Ha J, He M. The Association between Vision Impairment and Incidence of Dementia and Cognitive Impairment: A Systematic Review and Meta-analysis. Ophthalmology. 2021;128(8):1135\u201349.","journal-title":"Ophthalmology"},{"issue":"2","key":"1545_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1001\/jamainternmed.2021.6990","volume":"182","author":"CS Lee","year":"2022","unstructured":"Lee CS, Gibbons LE, Lee AY, et al. Association between cataract extraction and development of dementia. JAMA Intern Med. 2022;182(2):134\u201341. https:\/\/doi.org\/10.1001\/jamainternmed.2021.6990.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"1545_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrneurol.2012.227","volume":"9","author":"A London","year":"2013","unstructured":"London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2013;9(1):44\u201353.","journal-title":"Nat Rev Neurol"},{"key":"1545_CR37","doi-asserted-by":"publisher","first-page":"100899","DOI":"10.1016\/j.preteyeres.2020.100899","volume":"82","author":"VB Gupta","year":"2021","unstructured":"Gupta VB, Chitranshi N, den Haan J, Mirzaei M, You YY, Lim JK, et al. Retinal changes in Alzheimer\u2019s disease- integrated prospects of imaging, functional and molecular advances. Prog Retin Eye Res. 2021;82:100899.","journal-title":"Prog Retin Eye Res."},{"issue":"1","key":"1545_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/jamaophthalmol.2022.4845","volume":"141","author":"E Costanzo","year":"2023","unstructured":"Costanzo E, Lengyel I, Parravano M, Biagini I, Veldsman M, Badhwar A, et al. Ocular Biomarkers for Alzheimer Disease Dementia: An Umbrella Review of Systematic Reviews and Meta-analyses. JAMA Ophthalmol. 2023;141(1):84\u201391.","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"1545_CR39","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/jnnp-2020-325347","volume":"92","author":"CY Cheung","year":"2021","unstructured":"Cheung CY, Mok V, Foster PJ, Trucco E, Chen C, Wong TY. Retinal imaging in Alzheimer\u2019s disease. J Neurol Neurosur Ps. 2021;92(9):983\u201394.","journal-title":"J Neurol Neurosur Ps"},{"issue":"1","key":"1545_CR40","doi-asserted-by":"publisher","first-page":"e12232","DOI":"10.1002\/dad2.12232","volume":"13","author":"L Csincsik","year":"2021","unstructured":"Csincsik L, Quinn N, Yong KXX, Crutch SJ, Peto T, Lengyel I. Retinal phenotyping of variants of Alzheimer\u2019s disease using ultra-widefield retinal images. Alzheimers Dement (Amst). 2021;13(1):e12232.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1545_CR41","doi-asserted-by":"publisher","first-page":"720167","DOI":"10.3389\/fnagi.2021.720167","volume":"13","author":"A Majeed","year":"2021","unstructured":"Majeed A, Marwick B, Yu H, Fadavi H, Tavakoli M. Ophthalmic Biomarkers for Alzheimer\u2019s Disease: A Review. Front Aging Neurosci. 2021;13:720167.","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"1545_CR42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-023-02548-2","volume":"145","author":"Y Koronyo","year":"2023","unstructured":"Koronyo Y, Rentsendorj A, Mirzaei N, Regis GC, Sheyn J, Shi H, et al. Retinal pathological features and proteome signatures of Alzheimer\u2019s disease. Acta Neuropathol. 2023;145(4):409\u201338.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"1545_CR43","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.3390\/ijms22052360","volume":"22","author":"L Wang","year":"2021","unstructured":"Wang L, Mao X. Role of Retinal Amyloid-\u03b2 in Neurodegenerative Diseases: Overlapping Mechanisms and Emerging Clinical Applications. Int J Mol Sci. 2021;22(5):2360.","journal-title":"Int J Mol Sci."},{"issue":"4","key":"1545_CR44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.preteyeres.2011.02.004","volume":"30","author":"K Ohno-Matsui","year":"2011","unstructured":"Ohno-Matsui K. Parallel findings in age-related macular degeneration and Alzheimer\u2019s disease. Prog Retin Eye Res. 2011;30(4):217\u201338.","journal-title":"Prog Retin Eye Res"},{"key":"1545_CR45","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fnagi.2017.00214","volume":"9","author":"AI Ramirez","year":"2017","unstructured":"Ramirez AI, de Hoz R, Salobrar-Garcia E, Salazar JJ, Rojas B, Ajoy D, et al. The Role of Microglia in Retinal Neurodegeneration: Alzheimer\u2019s Disease, Parkinson, and Glaucoma. Front Aging Neurosci. 2017;9:214.","journal-title":"Front Aging Neurosci."},{"issue":"4","key":"1545_CR46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/vision4040046","volume":"4","author":"P Dickens","year":"2020","unstructured":"Dickens P, Ramaesh K. The evolving role of ophthalmology clinics in screening for early Alzheimer\u2019s disease: a review. Vision. 2020;4(4):46.","journal-title":"Vision."},{"issue":"5","key":"1545_CR47","doi-asserted-by":"publisher","first-page":"e2210740","DOI":"10.1001\/jamanetworkopen.2022.10740","volume":"5","author":"NS Reed","year":"2022","unstructured":"Reed NS, Oh ES. New Insights Into Sensory Impairment and Dementia Risk. JAMA Netw Open. 2022;5(5):e2210740.","journal-title":"JAMA Netw Open."},{"issue":"11","key":"1545_CR48","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.15506","volume":"66","author":"HE Whitson","year":"2018","unstructured":"Whitson HE, Cronin-Golomb A, Cruickshanks KJ, Gilmore GC, Owsley C, Peelle JE, et al. American Geriatrics Society and National Institute on Aging Bench-to-Bedside Conference: Sensory Impairment and Cognitive Decline in Older Adults. J Am Geriatr Soc. 2018;66(11):2052\u20138.","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"1545_CR49","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00401-016-1609-2","volume":"132","author":"BM Davis","year":"2016","unstructured":"Davis BM, Crawley L, Pahlitzsch M, Javaid F, Cordeiro MF. Glaucoma: the retina and beyond. Acta Neuropathol. 2016;132(6):807\u201326.","journal-title":"Acta Neuropathol"},{"issue":"8","key":"1545_CR50","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/eye.2015.100","volume":"29","author":"JA Ratnayaka","year":"2015","unstructured":"Ratnayaka JA, Serpell LC, Lotery AJ. Dementia of the eye: the role of amyloid beta in retinal degeneration. Eye. 2015;29(8):1013\u201326.","journal-title":"Eye"},{"key":"1545_CR51","doi-asserted-by":"publisher","first-page":"1371745","DOI":"10.3389\/fnagi.2024.1371745","volume":"16","author":"M Rinaldi","year":"2024","unstructured":"Rinaldi M, Pezone A, Quadrini GI, Abbadessa G, Laezza MP, Passaro ML, et al. Targeting shared pathways in tauopathies and age-related macular degeneration: implications for novel therapies. Front Aging Neurosci. 2024;16:1371745.","journal-title":"Front Aging Neurosci."},{"issue":"2","key":"1545_CR52","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1001\/jamainternmed.2021.6990","volume":"182","author":"CS Lee","year":"2022","unstructured":"Lee CS, Gibbons LE, Lee AY, Yanagihara RT, Blazes MS, Lee ML, et al. Association Between Cataract Extraction and Development of Dementia. Jama Intern Med. 2022;182(2):134\u201341.","journal-title":"Jama Intern Med"},{"issue":"9","key":"1545_CR53","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.biopsych.2022.06.005","volume":"93","author":"L-Z Ma","year":"2023","unstructured":"Ma L-Z, Zhang Y-R, Li Y-Z, Ou Y-N, Yang L, Chen S-D, et al. Cataract, Cataract Surgery, and Risk of Incident Dementia: A Prospective Cohort Study of 300,823 Participants. Biol Psychiat. 2023;93(9):810\u20139.","journal-title":"Biol Psychiat"},{"issue":"6","key":"1545_CR54","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1001\/jamaneurol.2022.0723","volume":"79","author":"JR Ehrlich","year":"2022","unstructured":"Ehrlich JR, Goldstein J, Swenor BK, Whitson H, Langa KM, Veliz P. Addition of Vision Impairment to a Life-Course Model of Potentially Modifiable Dementia Risk Factors in the US. Jama Neurol. 2022;79(6):623\u20136.","journal-title":"Jama Neurol"},{"issue":"6","key":"1545_CR55","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jamaneurol.2022.0092","volume":"79","author":"J Deal","year":"2022","unstructured":"Deal J, Rojas JC. Visual Impairment as a Modifiable Risk Factor in Dementia Prevention and Management. Jama Neurol. 2022;79(6):542\u20133.","journal-title":"Jama Neurol"},{"issue":"10248","key":"1545_CR56","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413\u201346.","journal-title":"Lancet"},{"issue":"4","key":"1545_CR57","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","volume":"9","author":"MJ Burton","year":"2021","unstructured":"Burton MJ, Ramke J, Marques AP, Bourne RRA, Congdon N, Jones I, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021;9(4):e489\u2013551.","journal-title":"Lancet Glob Health"},{"issue":"11","key":"1545_CR58","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1017\/S104161021700120X","volume":"29","author":"A Pye","year":"2017","unstructured":"Pye A, Charalambous AP, Leroi I, Thodi C, Dawes P. Screening tools for the identification of dementia for adults with age-related acquired hearing or vision impairment: a scoping review. Int Psychogeriatr. 2017;29(11):1771\u201384.","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"1545_CR59","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1038\/s41598-022-07924-8","volume":"12","author":"A Macnamara","year":"2022","unstructured":"Macnamara A, Schinazi VR, Chen C, Coussens S, Loetscher T. The effect of age-related macular degeneration on cognitive test performance. Sci Rep. 2022;12(1):4033.","journal-title":"Sci Rep"},{"issue":"5","key":"1545_CR60","first-page":"201","volume":"74","author":"KR Jongsma","year":"2016","unstructured":"Jongsma KR, van Bruchem-Visser RL, van de Vathorst S, Mattace Raso FUS. Has dementia research lost its sense of reality? A descriptive analysis of eligibility criteria of Dutch dementia research protocols. (1872\u20139061 (Electronic)). Neth J Med. 2016;74(5):201\u20139.","journal-title":"Neth J Med"},{"issue":"10","key":"1545_CR61","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1377\/hlthaff.2022.00520","volume":"41","author":"PW DeCormier","year":"2022","unstructured":"DeCormier PW, Ne\u2019eman A, Silverman BC, Strauss DH, Francis LP, Stein MA, Bierer BE. Excluding People With Disabilities From Clinical Research: Eligibility Criteria Lack Clarity And Justification. Health Aff (Millwood). 2022;41(10):1423\u201332.","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"1545_CR62","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/alz.12433","volume":"18","author":"S Franzen","year":"2022","unstructured":"Franzen S, Smith JE, van den Berg E, Rivera Mindt M, van Bruchem-Visser RL, Abner EL, et al. Diversity in Alzheimer\u2019s disease drug trials: The importance of eligibility criteria. Alzheimers Dement. 2022;18(4):810\u201323.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1545_CR63","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41398-022-02243-y","volume":"12","author":"MA Beydoun","year":"2022","unstructured":"Beydoun MA, Beydoun HA, Banerjee S, Weiss J, Evans MK, Zonderman AB. Pathways explaining racial\/ethnic and socio-economic disparities in incident all-cause dementia among older US adults across income groups. Transl Psychiat. 2022;12(1):478.","journal-title":"Transl Psychiat."},{"issue":"7","key":"1545_CR64","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1001\/jamapsychiatry.2018.1012","volume":"75","author":"D Cadar","year":"2018","unstructured":"Cadar D, Lassale C, Davies H, Llewellyn DJ, Batty GD, Steptoe A. Individual and area-based socioeconomic factors associated with dementia incidence in England: evidence from a 12-year follow-up in the English Longitudinal Study of Ageing. JAMA Psychiatry. 2018;75(7):723\u201332.","journal-title":"JAMA Psychiatry."},{"issue":"7","key":"1545_CR65","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/aje\/kwx155","volume":"186","author":"JR Marden","year":"2017","unstructured":"Marden JR, Tchetgen EJT, Kawachi I, Glymour MM. Contribution of Socioeconomic Status at 3 Life-Course Periods to Late-Life Memory Function and Decline: Early and Late Predictors of Dementia Risk. Am J Epidemiol. 2017;186(7):805\u201314.","journal-title":"Am J Epidemiol"},{"issue":"8","key":"1545_CR66","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1037\/neu0000579","volume":"33","author":"AE Werry","year":"2019","unstructured":"Werry AE, Daniel M, Bergstrom B. Group Differences in Normal Neuropsychological Test Performance for Older Non-Hispanic White and Black\/African American Adults. Neuropsychology. 2019;33(8):1089\u2013100.","journal-title":"Neuropsychology"},{"issue":"14","key":"1545_CR67","doi-asserted-by":"publisher","first-page":"e1424","DOI":"10.1212\/WNL.0000000000207674","volume":"101","author":"L Abigail","year":"2023","unstructured":"Abigail L, Aditi G, Inez O, Suzanne ES, Nupur G, Zachary A, et al. The Association Between Socioeconomic Factors, Race, and Usage of a Specialty Memory Clinic. Neurology. 2023;101(14):e1424\u201333. https:\/\/doi.org\/10.1212\/WNL.0000000000207674.","journal-title":"Neurology."},{"issue":"11","key":"1545_CR68","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jamaneurol.2022.2274","volume":"79","author":"JD Grill","year":"2022","unstructured":"Grill JD, Sperling RA, Raman R. What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials? Jama Neurol. 2022;79(11):1097\u20138.","journal-title":"Jama Neurol"},{"key":"1545_CR69","doi-asserted-by":"publisher","first-page":"1278944","DOI":"10.3389\/fpsyt.2023.1278944","volume":"14","author":"J Siette","year":"2023","unstructured":"Siette J, Meka A, Antoniades J. Breaking the barriers: overcoming dementia-related stigma in minority communities. Front Psychiatry. 2023;14:1278944.","journal-title":"Front Psychiatry."},{"issue":"3","key":"1545_CR70","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","volume":"20","author":"J Graff-Radford","year":"2021","unstructured":"Graff-Radford J, Yong KXX, Apostolova LG, Bouwman FH, Carrillo M, Dickerson BC, et al. New insights into atypical Alzheimer\u2019s disease in the era of biomarkers. Lancet Neurol. 2021;20(3):222\u201334.","journal-title":"Lancet Neurol"},{"issue":"Suppl 9","key":"1545_CR71","first-page":"S126","volume":"19 Suppl 9","author":"P Griffin","year":"2023","unstructured":"Griffin P, Apostolova L, Dickerson BC, Rabinovici G, Salloway S, Brandt K, et al. Developments in understanding early onset Alzheimer\u2019s disease. Alzheimers Dement. 2023;19 Suppl 9(Suppl 9):S126\u201331.","journal-title":"Alzheimers Dement."},{"issue":"2","key":"1545_CR72","doi-asserted-by":"publisher","first-page":"e018663","DOI":"10.1136\/bmjopen-2017-018663","volume":"8","author":"H Emma","year":"2018","unstructured":"Emma H, Mary Pat S, Rachel W, Keir XXY, Anne M, Mary LG, et al. \u2018Because my brain isn\u2019t as active as it should be, my eyes don\u2019t always see\u2019: a qualitative exploration of the stress process for those living with posterior cortical atrophy. BMJ Open. 2018;8(2):e018663.","journal-title":"BMJ Open"},{"issue":"8","key":"1545_CR73","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jalz.2017.01.014","volume":"13","author":"SJ Crutch","year":"2017","unstructured":"Crutch SJ, Schott JM, Rabinovici GD, Murray M, Snowden JS, van der Flier WM, et al. Consensus classification of posterior cortical atrophy. Alzheimers Dement. 2017;13(8):870\u201384.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1545_CR74","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S1474-4422(23)00414-3","volume":"23","author":"M Chapleau","year":"2024","unstructured":"Chapleau M, La Joie R, Yong K, Agosta F, Allen IE, Apostolova L, et al. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis. The Lancet Neurology. 2024;23(2):168\u201377.","journal-title":"The Lancet Neurology"},{"issue":"2","key":"1545_CR75","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11940-022-00745-0","volume":"25","author":"KXX Yong","year":"2023","unstructured":"Yong KXX, Graff-Radford J, Ahmed S, Chapleau M, Ossenkoppele R, Putcha D, et al. Diagnosis and Management of Posterior Cortical Atrophy. Curr Treat Options Neurol. 2023;25(2):23\u201343.","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"1545_CR76","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/WCO.0000000000000767","volume":"33","author":"SK Holden","year":"2020","unstructured":"Holden SK, Bettcher BM, Pelak VS. Update on posterior cortical atrophy. Curr Opin Neurol. 2020;33(1):68\u201373.","journal-title":"Curr Opin Neurol"},{"issue":"8","key":"1545_CR77","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/alz.12511","volume":"18","author":"CE Gleason","year":"2022","unstructured":"Gleason CE, Zuelsdorff M, Gooding DC, Kind AJH, Johnson AL, James TT, et al. Alzheimer\u2019s disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence. Alzheimers Dement. 2022;18(8):1545\u201364.","journal-title":"Alzheimers Dement"},{"key":"1545_CR78","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fnagi.2016.00296","volume":"8","author":"JC Howell","year":"2016","unstructured":"Howell JC, Parker MW, Watts KD, Kollhoff A, Tsvetkova DZ, Hu WT. Research Lumbar Punctures among African Americans and Caucasians: Perception Predicts Experience. Front Aging Neurosci. 2016;8:296.","journal-title":"Front Aging Neurosci."},{"issue":"12","key":"1545_CR79","doi-asserted-by":"publisher","first-page":"e12921","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Suarez-Calvet","year":"2020","unstructured":"Suarez-Calvet M, Karikari TK, Ashton NJ, Rodriguez JL, Mila-Aloma M, Gispert JD, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A beta pathology are detected. Embo Mol Med. 2020;12(12):e12921.","journal-title":"Embo Mol Med."},{"key":"1545_CR80","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/brain\/awaa399","volume":"144","author":"A Moscoso","year":"2021","unstructured":"Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Rodriguez JL, Snellman A, et al. Time course of phosphorylated-tau181 in blood across the Alzheimer\u2019s disease spectrum. Brain. 2021;144:325\u201339.","journal-title":"Brain"},{"issue":"9","key":"1545_CR81","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K, et al. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. Jama Neurol. 2021;78(9):1108\u201317.","journal-title":"Jama Neurol"},{"issue":"7","key":"1545_CR82","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/alz.12283","volume":"17","author":"J Simren","year":"2021","unstructured":"Simren J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers & Dementia. 2021;17(7):1145\u201356.","journal-title":"Alzheimers & Dementia"},{"issue":"3","key":"1545_CR83","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26(3):379\u201386.","journal-title":"Nat Med"},{"issue":"7","key":"1545_CR84","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L, et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol. 2022;18(7):400\u201318.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"1545_CR85","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387\u201397.","journal-title":"Nat Med"},{"issue":"S4","key":"1545_CR86","doi-asserted-by":"publisher","first-page":"e042489","DOI":"10.1002\/alz.042489","volume":"16","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Smith R, Stomrud E, Palmqvist S, Dage JL, Hansson O. Plasma phospho-tau217 is a potential early diagnostic and prognostic biomarker of Alzheimer\u2019s disease. Alzheimers Dement. 2020;16(S4):e042489.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"1545_CR87","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. The Lancet Neurology. 2021;20(9):739\u201352.","journal-title":"The Lancet Neurology"},{"issue":"9","key":"1545_CR88","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1093\/brain\/awab163","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Stomrud E, Palmqvist S, van Westen D, Dage JL, et al. Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain. 2021;144(9):2826\u201336.","journal-title":"Brain"},{"issue":"12","key":"1545_CR89","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, et al. Differential roles of Abeta42\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28(12):2555\u201362.","journal-title":"Nat Med"},{"issue":"3","key":"1545_CR90","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","volume":"140","author":"JL Rodriguez","year":"2020","unstructured":"Rodriguez JL, Karikari TK, Suarez-Calvet M, Troakes C, King A, Emersic A, et al. Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020;140(3):267\u201378.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1545_CR91","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy S, Verberk IMW, den Dulk B, Hussainali Z, Zwan M, van der Flier WM, et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res Ther. 2021;13(1):198.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1545_CR92","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13024-023-00605-8","volume":"18","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK. Plasma phospho-tau in Alzheimer\u2019s disease: towards diagnostic and therapeutic trial applications. Mol Neurodegener. 2023;18(1):18.","journal-title":"Mol Neurodegener"},{"issue":"5","key":"1545_CR93","doi-asserted-by":"publisher","first-page":"e17123","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3 G, Ossenkoppele R, Ashton NJ, Beach TG, Serrano GE, Reiman EM, et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. Embo Mol Med. 2023;15(5):e17123.","journal-title":"Embo Mol Med"},{"issue":"17","key":"1545_CR94","doi-asserted-by":"publisher","first-page":"e1681","DOI":"10.1212\/WNL.0000000000012727","volume":"97","author":"A Leuzy","year":"2021","unstructured":"Leuzy A, Janelidze S, Mattsson-Carlgren N, Palmqvist S, Jacobs D, Cicognola C, et al. Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology. 2021;97(17):e1681\u201394.","journal-title":"Neurology"},{"issue":"2","key":"1545_CR95","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, et al. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. Jama Neurol. 2021;78(2):149\u201356.","journal-title":"Jama Neurol"},{"issue":"1","key":"1545_CR96","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/alz.13529","volume":"20","author":"J Alber","year":"2024","unstructured":"Alber J, Bouwman F, den Haan J, Rissman RA, De Groef L, Koronyo-Hamaoui M, et al. Retina pathology as a target for biomarkers for Alzheimer\u2019s disease: Current status, ophthalmopathological background, challenges, and future directions. Alzheimers Dement. 2024;20(1):728\u201340.","journal-title":"Alzheimers Dement"},{"key":"1545_CR97","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.trci.2019.09.006","volume":"5","author":"SM Sharafi","year":"2019","unstructured":"Sharafi SM, Sylvestre JP, Chevrefils C, Soucy JP, Beaulieu S, Pascoal TA, et al. Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images. Alzheimers Dement (N Y). 2019;5:610\u20137.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"1545_CR98","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1038\/s41467-019-12242-1","volume":"10","author":"X Hadoux","year":"2019","unstructured":"Hadoux X, Hui F, Lim JKH, Masters CL, Pebay A, Chevalier S, et al. Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer\u2019s disease. Nat Commun. 2019;10(1):4227.","journal-title":"Nat Commun"},{"issue":"7","key":"1545_CR99","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1167\/iovs.15-17406","volume":"57","author":"SS More","year":"2016","unstructured":"More SS, Beach JM, Vince R. Early Detection of Amyloidopathy in Alzheimer\u2019s Mice by Hyperspectral Endoscopy. Invest Ophth Vis Sci. 2016;57(7):3231\u20138.","journal-title":"Invest Ophth Vis Sci"},{"issue":"2","key":"1545_CR100","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1021\/cn500242z","volume":"6","author":"SS More","year":"2015","unstructured":"More SS, Vince R. Hyperspectral Imaging Signatures Detect Amyloidopathy in Alzheimer\u2019s Mouse Retina Well before Onset of Cognitive Decline. ACS Chem Neurosci. 2015;6(2):306\u201315.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"1545_CR101","doi-asserted-by":"publisher","first-page":"6387","DOI":"10.1038\/s41598-021-85554-2","volume":"11","author":"JKH Lim","year":"2021","unstructured":"Lim JKH, Li QX, Ryan T, Bedggood P, Metha A, Vingrys AJ, et al. Retinal hyperspectral imaging in the 5xFAD mouse model of Alzheimer\u2019s disease. Sci Rep-Uk. 2021;11(1):6387.","journal-title":"Sci Rep-Uk."},{"issue":"S5","key":"1545_CR102","doi-asserted-by":"publisher","first-page":"e054582","DOI":"10.1002\/alz.054582","volume":"17","author":"J-P Soucy","year":"2021","unstructured":"Soucy J-P, Chevrefils C, Osseiran S, Sylvestre J-P, Lesage F, Beaulieu S, et al. A retinal deep phenotypingTM platform to predict the cerebral amyloid PET status in older adults. Alzheimers Dement. 2021;17(S5):e054582.","journal-title":"Alzheimers Dement"},{"issue":"S4","key":"1545_CR103","doi-asserted-by":"publisher","first-page":"e043395","DOI":"10.1002\/alz.043395","volume":"16","author":"J-P Soucy","year":"2020","unstructured":"Soucy J-P, Chevrefils C, Osseiran S, Sylvestre J-P, Beaulieu S, Pascoal TA, et al. Evaluation of a retinal deep phenotyping platform to detect the likely cerebral amyloid PET status in humans. Alzheimers Dement. 2020;16(S4):e043395.","journal-title":"Alzheimers Dement"},{"issue":"7S_Part_2","key":"1545_CR104","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jalz.2018.06.2257","volume":"14","author":"J-P Soucy","year":"2018","unstructured":"Soucy J-P, Chevrefils C, Sylvestre J-P, Arbour JD, Rh\u00e9aume M-A, Beaulieu S, et al. IC-P-190: An amyloid ligand-free optical retinal imaging method to predict cerebral amyloid pet status. Alzheimer\u2019s and Dementia. 2018;14(7S_Part_2):158.","journal-title":"Alzheimer's and Dementia."},{"issue":"11","key":"1545_CR105","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1021\/acschemneuro.9b00331","volume":"10","author":"SS More","year":"2019","unstructured":"More SS, Beach JM, McClelland C, Mokhtarzadeh A, Vince R. In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer\u2019s Disease. ACS Chem Neurosci. 2019;10(11):4492\u2013501.","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"1545_CR106","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3233\/JAD-210327","volume":"83","author":"K Tadokoro","year":"2021","unstructured":"Tadokoro K, Yamashita T, Kimura S, Nomura E, Ohta Y, Omote Y, et al. Retinal Amyloid Imaging for Screening Alzheimer\u2019s Disease. J Alzheimers Dis. 2021;83(2):927\u201334.","journal-title":"J Alzheimers Dis"},{"key":"1545_CR107","doi-asserted-by":"publisher","first-page":"101273","DOI":"10.1016\/j.preteyeres.2024.101273","volume":"101","author":"BP Gaire","year":"2024","unstructured":"Gaire BP, Koronyo Y, Fuchs D-T, Shi H, Rentsendorj A, Danziger R, et al. Alzheimer\u2019s disease pathophysiology in the Retina. Prog Retin Eye Res. 2024;101:101273.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"1545_CR108","first-page":"e12083","volume":"12","author":"HFM Rhodius-Meester","year":"2020","unstructured":"Rhodius-Meester HFM, Paajanen T, Koikkalainen J, Mahdiani S, Bruun M, Baroni M, et al. cCOG: A web-based cognitive test tool for detecting neurodegenerative disorders. Alzh Dement-Dadm. 2020;12(1):e12083.","journal-title":"Alzh Dement-Dadm"},{"issue":"2","key":"1545_CR109","doi-asserted-by":"publisher","first-page":"e12401","DOI":"10.1002\/trc2.12401","volume":"9","author":"MAE Dreves","year":"2023","unstructured":"Dreves MAE, van Harten AC, Visser LNC, Rhodius-Meester H, Kohler S, Kooistra M, et al. Rationale and design of the ABOARD project (A Personalized Medicine Approach for Alzheimer\u2019s Disease). Alzheimers Dement (N Y). 2023;9(2):e12401.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"3","key":"1545_CR110","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","volume":"79","author":"WJ Jansen","year":"2022","unstructured":"Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ. Amyloid Biomarker Study G. prevalence estimates ofamyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol. 2022;79(3):228\u201343.","journal-title":"JAMA Neurol."},{"issue":"2","key":"1545_CR111","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 2023;80(2):188\u201399. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4485.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1545_CR112","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12874-022-01694-7","volume":"22","author":"L Naing","year":"2022","unstructured":"Naing L, Nordin RB, Abdul Rahman H, Naing YT. Sample size calculation for prevalence studies using Scalex and ScalaR calculators. BMC Med Res Methodol. 2022;22(1):209.","journal-title":"BMC Med Res Methodol"},{"key":"1545_CR113","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. J Alzheimers Dis. 2018;62:1091\u2013111.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"1545_CR114","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","volume":"18","author":"IMW Verberk","year":"2022","unstructured":"Verberk IMW, Misdorp EO, Koelewijn J, Ball AJ, Blennow K, Dage JL, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease-related blood-based biomarkers: Results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group. Alzheimers Dement. 2022;18(8):1484\u201397.","journal-title":"Alzheimers Dement"},{"issue":"17","key":"1545_CR115","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647\u201359.","journal-title":"Neurology"},{"issue":"2","key":"1545_CR116","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","volume":"2","author":"IMW Verberk","year":"2021","unstructured":"Verberk IMW, Laarhuis MB, van den Bosch KA, Ebenau JL, van Leeuwenstijn M, Prins ND, et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev. 2021;2(2):e87\u201395.","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"1545_CR117","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13195-022-00990-0","volume":"14","author":"A Pichet Binette","year":"2022","unstructured":"Pichet Binette A, Palmqvist S, Bali D, Farrar G, Buckley CJ, Wolk DA, et al. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer\u2019s dementia in mild cognitive impairment patients. Alzheimers Res Ther. 2022;14(1):46.","journal-title":"Alzheimers Res Ther."},{"issue":"8","key":"1545_CR118","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jalz.2016.01.010","volume":"12","author":"JM Schott","year":"2016","unstructured":"Schott JM, Crutch SJ, Carrasquillo MM, Uphill J, Shakespeare TJ, Ryan NS, et al. Genetic risk factors for the posterior cortical atrophy variant of Alzheimer\u2019s disease. Alzheimers Dement. 2016;12(8):862\u201371.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1545_CR119","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaophthalmol.2022.4602","volume":"141","author":"KL Rasmussen","year":"2023","unstructured":"Rasmussen KL, Tybj\u00e6rg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Associations of Alzheimer Disease-Protective APOE Variants With Age-Related Macular Degeneration. JAMA Ophthalmology. 2023;141(1):13\u201321.","journal-title":"JAMA Ophthalmology"},{"issue":"9","key":"1545_CR120","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.immuni.2022.07.014","volume":"55","author":"MA Margeta","year":"2022","unstructured":"Margeta MA, Yin Z, Madore C, Pitts KM, Letcher SM, Tang J, et al. Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucoma. Immunity. 2022;55(9):1627\u201344.e7.","journal-title":"Immunity"},{"issue":"8","key":"1545_CR121","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/iovs.61.8.3","volume":"61","author":"MA Margeta","year":"2020","unstructured":"Margeta MA, Letcher SM, Igo RP Jr, Cooke Bailey JN, Pasquale LR, Haines JL, et al. Association of APOE With Primary Open-Angle Glaucoma Suggests a Protective Effect for APOE \u03b54. Invest Ophth Vis Sci. 2020;61(8):3.","journal-title":"Invest Ophth Vis Sci."},{"key":"1545_CR122","unstructured":"Centraal Bureau voor de Statistiek - Nieuwe indeling bevolking naar herkomst CBS2022. Available from: https:\/\/www.cbs.nl\/nl-nl\/longread\/statistische-trends\/2022\/nieuwe-indeling-bevolking-naar-herkomst."},{"issue":"2","key":"1545_CR123","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1212\/WNL.0000000000004802","volume":"90","author":"C Groot","year":"2018","unstructured":"Groot C, Van Loenhoud AC, Barkhof F, Van Berckel BNM, Koene T, Teunissen CC, et al. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology. 2018;90(2):e149\u201356.","journal-title":"Neurology"},{"issue":"9","key":"1545_CR124","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1002\/hbm.23695","volume":"38","author":"AC van Loenhoud","year":"2017","unstructured":"van Loenhoud AC, Wink AM, Groot C, Verfaillie SCJ, Twisk J, Barkhof F, et al. A neuroimaging approach to capture cognitive reserve: Application to Alzheimer\u2019s disease. Hum Brain Mapp. 2017;38(9):4703\u201315.","journal-title":"Hum Brain Mapp"},{"issue":"1","key":"1545_CR125","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13195-019-0570-4","volume":"11","author":"AC van Loenhoud","year":"2019","unstructured":"van Loenhoud AC, de Boer C, Wols K, Pijnenburg YA, Lemstra AW, Bouwman FH, et al. High occurrence of transportation and logistics occupations among vascular dementia patients: an observational study. Alzheimers Res Ther. 2019;11(1):112.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1545_CR126","doi-asserted-by":"publisher","first-page":"10767","DOI":"10.1038\/s41598-021-90188-5","volume":"11","author":"F Rezaei","year":"2021","unstructured":"Rezaei F, Seif M, Gandomkar A, Fattahi MR, Hasanzadeh J. Agreement between laboratory-based and non-laboratory-based Framingham risk score in Southern Iran. Sci Rep-Uk. 2021;11(1):10767.","journal-title":"Sci Rep-Uk."},{"issue":"4","key":"1545_CR127","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/tvst.11.4.5","volume":"11","author":"TP Rausch-Koster","year":"2022","unstructured":"Rausch-Koster TP, Luijten MAJ, Verbraak FD, van Rens G, van Nispen RMA. Calibration of the Dutch EyeQ to Measure Vision Related Quality of Life in Patients With Exudative Retinal Diseases. Transl Vis Sci Technol. 2022;11(4):5.","journal-title":"Transl Vis Sci Technol"},{"issue":"4","key":"1545_CR128","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"S8","key":"1545_CR129","doi-asserted-by":"publisher","first-page":"e057817","DOI":"10.1002\/alz.057817","volume":"17","author":"ZS Nasreddine","year":"2021","unstructured":"Nasreddine ZS. MoCA Test: Validation of a five-minute telephone version. Alzheimers Dement. 2021;17(S8):e057817.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1545_CR130","first-page":"e12144","volume":"13","author":"MJ Katz","year":"2021","unstructured":"Katz MJ, Wang CL, Nester CO, Derby CA, Zimmerman ME, Lipton RB, et al. T-MoCA: A valid phone screen for cognitive impairment in diverse community samples. Alzh Dement-Dadm. 2021;13(1):e12144.","journal-title":"Alzh Dement-Dadm."},{"key":"1545_CR131","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40942-016-0035-x","volume":"2","author":"M Yung","year":"2016","unstructured":"Yung M, Klufas MA, Sarraf D. Clinical applications of fundus autofluorescence in retinal disease. Int J Retina Vitreous. 2016;2:12.","journal-title":"Int J Retina Vitreous"},{"issue":"1","key":"1545_CR132","first-page":"169","volume":"4","author":"PJ Snyder","year":"2016","unstructured":"Snyder PJ, Johnson LN, Lim YY, Santos CY, Alber J, Maruff P, Fern\u00e1ndez B. Nonvascular retinal imaging markers of preclinical Alzheimer\u2019s disease. Alzh Dement-Dadm. 2016;4(1):169\u201378.","journal-title":"Alzh Dement-Dadm"},{"issue":"11","key":"1545_CR133","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28(11):2381\u20137.","journal-title":"Nat Med"},{"issue":"10","key":"1545_CR134","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvad\u00f3 G, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49(10):3508\u201328.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Supplement 1","key":"1545_CR135","doi-asserted-by":"publisher","first-page":"20S","DOI":"10.2967\/jnumed.121.263196","volume":"63","author":"G Colin","year":"2022","unstructured":"Colin G, Sylvia V, Ruben S, Oskar H, Rik O. Tau PET Imaging in Neurodegenerative Disorders. J Nucl Med. 2022;63(Supplement 1):20S.","journal-title":"J Nucl Med"},{"issue":"7","key":"1545_CR136","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK, Truocchio SP, et al. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. Jama Neurol. 2020;77(7):829\u201339.","journal-title":"Jama Neurol"},{"issue":"3","key":"1545_CR137","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of Florbetapir-PET for Imaging \u03b2-Amyloid Pathology. JAMA. 2011;305(3):275\u201383.","journal-title":"JAMA"},{"issue":"11","key":"1545_CR138","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Scholl M, Strandberg O, et al. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2018;320(11):1151\u201362.","journal-title":"JAMA"},{"issue":"1","key":"1545_CR139","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau Positron Emission Tomographic Imaging in Aging and Early Alzheimer Disease. Ann Neurol. 2016;79(1):110\u20139.","journal-title":"Ann Neurol"},{"issue":"3","key":"1545_CR140","first-page":"84","volume":"7","author":"C Breault","year":"2017","unstructured":"Breault C, Piper J, Joshi AD, Pirozzi SD, Nelson AS, Lu M, et al. Correlation between two methods of florbetapir PET quantitative analysis. Am J Nucl Med Molec. 2017;7(3):84\u201391.","journal-title":"Am J Nucl Med Molec"},{"issue":"10","key":"1545_CR141","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/jamaneurol.2015.1633","volume":"72","author":"S Schreiber","year":"2015","unstructured":"Schreiber S, Landau SM, Fero A, Schreiber F, Jagust WJ. Alzheimer\u2019s Disease Neuroimaging I. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes. JAMA Neurol. 2015;72(10):1183\u201390.","journal-title":"JAMA Neurol."},{"issue":"12","key":"1545_CR142","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s12149-022-01792-y","volume":"36","author":"H Matsuda","year":"2022","unstructured":"Matsuda H, Okita K, Motoi Y, Mizuno T, Ikeda M, Sanjo N, et al. Clinical impact of amyloid PET using 18F-florbetapir in patients with cognitive impairment and suspected Alzheimer\u2019s disease: a multicenter study. Ann Nucl Med. 2022;36(12):1039\u201349.","journal-title":"Ann Nucl Med"},{"issue":"3","key":"1545_CR143","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr","year":"2017","unstructured":"Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 2017;13(3):205\u201316.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1545_CR144","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"issue":"11","key":"1545_CR145","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.2967\/jnumed.114.153494","volume":"56","author":"DJ Abhinay","year":"2015","unstructured":"Abhinay DJ, Michael JP, Ming L, Daniel MS, Mark AM, Michael D, Devous Sr. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images. J Nuclear Med. 2015;56(11):1736.","journal-title":"J Nuclear Med"},{"issue":"1","key":"1545_CR146","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1017\/S135561772100148X","volume":"29","author":"S Franzen","year":"2023","unstructured":"Franzen S, van den Berg E, Ayhan Y, Satoer DD, Turkoglu O, Genc Akpulat GE, et al. The Naming Assessment in Multicultural Europe (NAME): Development and Validation in a Multicultural Memory Clinic. J Int Neuropsychol Soc. 2023;29(1):92\u2013104.","journal-title":"J Int Neuropsychol Soc"},{"issue":"3","key":"1545_CR147","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/13803395.2022.2105820","volume":"44","author":"SK Holden","year":"2022","unstructured":"Holden SK, Pelak VS, Sooy T, Heffernan KS, McConnell BV, Pressman PS, Bettcher BM. Development of the Colorado posterior cortical questionnaire within an Alzheimer\u2019s disease study cohort. J Clin Exp Neuropsyc. 2022;44(3):226\u201336.","journal-title":"J Clin Exp Neuropsyc"},{"issue":"3","key":"1545_CR148","first-page":"e12474","volume":"15","author":"VS Pelak","year":"2023","unstructured":"Pelak VS, Tang-Wai DF, Boeve BF, Bouwman FH, Graff-Radford J, Rabinovici G, et al. Consensus recommendations for clinical assessment tools for the diagnosis of posterior cortical atrophy syndrome from the Atypical AD PIA of ISTAART. Alzh Dement-Dadm. 2023;15(3):e12474.","journal-title":"Alzh Dement-Dadm"},{"issue":"4","key":"1545_CR149","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.trci.2017.10.004","volume":"3","author":"KV Papp","year":"2017","unstructured":"Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical Alzheimer\u2019s cognitive composite with semantic processing: The PACC5. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2017;3(4):668\u201377.","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"12","key":"1545_CR150","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1002\/alz.13410","volume":"19","author":"J van der Schaar","year":"2023","unstructured":"van der Schaar J, Visser LNC, Ket JCF, Groot C, Pijnenburg YAL, Scheltens P, et al. Impact of sharing Alzheimer\u2019s disease biomarkers with individuals without dementia: A systematic review and meta-analysis of empirical data. Alzheimer\u2019s Dement. 2023;19(12):5773\u201394.","journal-title":"Alzheimer's Dement."},{"issue":"3","key":"1545_CR151","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/alz.12328","volume":"17","author":"Alzheimer's disease facts and figures","year":"2021","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2021;17(3):327\u2013406.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1545_CR152","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/alz.12068","volume":"16","author":"Alzheimer's disease facts and figures","year":"2020","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2020;16(3):391\u2013460.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1545_CR153","doi-asserted-by":"publisher","first-page":"8698","DOI":"10.1038\/s41598-019-45055-9","volume":"9","author":"M Marquie","year":"2019","unstructured":"Marquie M, Castilla-Marti M, Valero S, Martinez J, Sanchez D, Hernandez I, et al. Visual impairment in aging and cognitive decline: experience in a Memory Clinic. Sci Rep-Uk. 2019;9(1):8698.","journal-title":"Sci Rep-Uk."},{"issue":"1","key":"1545_CR154","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13311-016-0481-z","volume":"14","author":"SE Counts","year":"2017","unstructured":"Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ. Biomarkers for the Early Detection and Progression of Alzheimer\u2019s Disease. Neurotherapeutics. 2017;14(1):35\u201353.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1545_CR155","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41398-024-02819-w","volume":"14","author":"C Wang","year":"2024","unstructured":"Wang C, Tachimori H, Yamaguchi H, Sekiguchi A, Li Y, Yamashita Y. for Alzheimer\u2019s Disease Neuroimaging I. A multimodal deep learning approach for the prediction of cognitive decline and its effectiveness in clinical trials for Alzheimer\u2019s disease. Transl Psychiat. 2024;14(1):105.","journal-title":"Transl Psychiat."},{"key":"1545_CR156","doi-asserted-by":"crossref","unstructured":"Mielke MM, Fowler NR. Alzheimer disease blood biomarkers: considerations for population-level use. Nat Rev Neurol. 2024.","DOI":"10.1038\/s41582-024-00989-1"},{"issue":"7","key":"1545_CR157","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD, Algeciras-Schimnich A, Knopman DS, Lowe VJ, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022;28(7):1398\u2013405.","journal-title":"Nat Med"},{"issue":"9","key":"1545_CR158","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/tvst.9.9.9","volume":"9","author":"S Lemmens","year":"2020","unstructured":"Lemmens S, Van Eijgen J, Van Keer K, Jacob J, Moylett S, De Groef L, et al. Hyperspectral Imaging and the Retina: Worth the Wave? Transl Vis Sci Technol. 2020;9(9):9.","journal-title":"Transl Vis Sci Technol"},{"issue":"3","key":"1545_CR159","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1167\/iovs.64.3.12","volume":"64","author":"BA Berkowitz","year":"2023","unstructured":"Berkowitz BA, Podolsky RH, Childers KL, Roberts R, Waseem R. Multiple Bioenergy-Linked OCT Biomarkers Suggest Greater-Than-Normal Rod Mitochondria Activity Early in Experimental Alzheimer\u2019s Disease. Invest Ophth Vis Sci. 2023;64(3):12.","journal-title":"Invest Ophth Vis Sci."},{"issue":"1","key":"1545_CR160","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3129\/i07-185","volume":"43","author":"N Gupta","year":"2008","unstructured":"Gupta N, Fong J, Ang LC, Yucel YH. Retinal tau pathology in human glaucomas. Can J Ophthalmol. 2008;43(1):53\u201360.","journal-title":"Can J Ophthalmol"},{"issue":"2","key":"1545_CR161","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00401-022-02534-0","volume":"145","author":"FJ Hart de Ruyter","year":"2023","unstructured":"FJ, Hart de Ruyter FJ, Morrema THJ, den Haan J, Netherlands Brain B, Twisk JWR, de Boer JF, et al. Correction to: Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer\u2019s disease and primary tauopathies. Acta Neuropathol. 2023;145(2):263.","journal-title":"Acta Neuropathol."},{"issue":"1","key":"1545_CR162","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s40478-018-0650-x","volume":"6","author":"J den Haan","year":"2018","unstructured":"den Haan J, Morrema THJ, Verbraak FD, de Boer JF, Scheltens P, Rozemuller AJ, et al. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer\u2019s disease retinas. Acta Neuropathol Commun. 2018;6(1):147.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"1545_CR163","doi-asserted-by":"publisher","first-page":"pgac164","DOI":"10.1093\/pnasnexus\/pgac164","volume":"1","author":"X Du","year":"2022","unstructured":"Du X, Koronyo Y, Mirzaei N, Yang C, Fuchs DT, Black KL, et al. Label-free hyperspectral imaging and deep-learning prediction of retinal amyloid beta-protein and phosphorylated tau. PNAS Nexus. 2022;1(4):pgac164.","journal-title":"PNAS Nexus."},{"key":"1545_CR164","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12886-015-0060-9","volume":"15","author":"PF Kaeser","year":"2015","unstructured":"Kaeser PF, Ghika J, Borruat FX. Visual signs and symptoms in patients with the visual variant of Alzheimer disease. BMC Ophthalmol. 2015;15:65.","journal-title":"BMC Ophthalmol"},{"key":"1545_CR165","doi-asserted-by":"publisher","first-page":"100020","DOI":"10.1016\/j.jfop.2023.100020","volume":"2","author":"KL Taylor","year":"2023","unstructured":"Taylor KL, Aebi BE. Do you want to know your future? A qualitative study of patient perspectives on knowing the risk of an incurable disease through ophthalmologic screening. JFO Open Ophthalmology. 2023;2:100020.","journal-title":"JFO Open Ophthalmology"},{"key":"1545_CR166","doi-asserted-by":"publisher","first-page":"1143128","DOI":"10.3389\/fneur.2023.1143128","volume":"14","author":"EE Broome","year":"2023","unstructured":"Broome EE, Tannirandorn P, Straus J, Beale P, Heffernan E, Dening T, Henshaw H. Patient perceptions of cognitive screening in adult audiology services: A qualitative exploration. Front Neurol. 2023;14:1143128.","journal-title":"Front Neurol"},{"key":"1545_CR167","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3233\/JAD-201081","volume":"80","author":"KK Indorewalla","year":"2021","unstructured":"Indorewalla KK, O\u2019Connor MK, Budson AE, Guess C, Jackson J. Modifiable Barriers for Recruitment and Retention of Older Adults Participants from Underrepresented Minorities in Alzheimer\u2019s Disease Research. J Alzheimers Dis. 2021;80:927\u201340.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"1545_CR168","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/alz.12737","volume":"19","author":"JB Langbaum","year":"2023","unstructured":"Langbaum JB, Zissimopoulos J, Au R, Bose N, Edgar CJ, Ehrenberg E, et al. Recommendations to address key recruitment challenges of Alzheimer\u2019s disease clinical trials. Alzheimers Dement. 2023;19(2):696\u2013707.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1545_CR169","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13195-017-0311-5","volume":"9","author":"MM Nu\u00f1o","year":"2017","unstructured":"Nu\u00f1o MM, Gillen DL, Dosanjh KK, Brook J, Elashoff D, Ringman JM, Grill JD. Attitudes toward clinical trials across the Alzheimer\u2019s disease spectrum. Alzheimer\u2019s Research & Therapy. 2017;9(1):81.","journal-title":"Alzheimer's Research & Therapy"},{"key":"1545_CR170","first-page":"751","volume":"5","author":"AL Gilmore-Bykovskyi","year":"2019","unstructured":"Gilmore-Bykovskyi AL, et al. Recruitment and retention of underrepresented populations in Alzheimer\u2019s disease research: A systematic review. Alzh Dement. 2019;5:751\u201370.","journal-title":"Alzh Dement"},{"issue":"4","key":"1545_CR171","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2214\/AJR.10.5956","volume":"196","author":"LT Dauer","year":"2011","unstructured":"Dauer LT, Thornton RH, Hay JL, Balter R, Williamson MJ, St GJ. Fears, feelings, and facts: interactively communicating benefits and risks of medical radiation with patients. AJR Am J Roentgenol. 2011;196(4):756\u201361.","journal-title":"AJR Am J Roentgenol"},{"key":"1545_CR172","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ajo.2022.11.005","volume":"247","author":"H-R Tsai","year":"2023","unstructured":"Tsai H-R, Lo RY, Liang K-H, Chen T-L, Huang H-K, Wang J-H, Lee Y-C. Risk of Subsequent Dementia or Alzheimer Disease Among Patients With Age-Related Macular Degeneration: A Systematic Review and Meta-analysis. Am J Ophthalmol. 2023;247:161\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1545_CR173","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ophtha.2023.10.014","volume":"131","author":"C Crump","year":"2023","unstructured":"Crump C, Sundquist J, Sieh W, Sundquist K. Risk of Alzheimer\u2019s Disease and Related Dementias in Persons With Glaucoma: A National Cohort Study. Ophthalmology. 2023;131(3):302\u20139.","journal-title":"Ophthalmology."},{"issue":"2","key":"1545_CR174","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00401-022-02525-1","volume":"145","author":"FJ Hart de Ruyter","year":"2023","unstructured":"Hart de Ruyter FJ, Morrema THJ, den Haan J, Twisk JWR, de Boer JF, Scheltens P, et al. Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer\u2019s disease and primary tauopathies. \u00a0Acta Neuropathol. 2023;145(2):197\u2013218.","journal-title":"\u00a0Acta Neuropathol."},{"key":"1545_CR175","unstructured":"Haoshen S, Nazanin M, Yosef K, Miyah RD, Edward R, Gila MB, et al. Identification of retinal tau oligomers, citrullinated tau, and other tau isoforms in early and advanced AD and relations to disease status. bioRxiv. 2024:2024.02.13.579999."},{"issue":"1","key":"1545_CR176","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1037\/0882-7974.12.1.12","volume":"12","author":"PB Baltes","year":"1997","unstructured":"Baltes PB, Lindenberger U. Emergence of a powerful connection between sensory and cognitive functions across the adult life span: a new window to the study of cognitive aging? Psychol Aging. 1997;12(1):12\u201321.","journal-title":"Psychol Aging"}],"container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01545-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01545-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01545-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:45:53Z","timestamp":1724409953000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01545-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":176,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1545"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01545-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The BeyeOMARKER study (Eudamed CIV ID: CIV-NL-23\u201309-044086) and the BeyeOMARKER biobank were approved by the ethical review board of the VU Medical Center (VUmc). All of the participants will be asked to provide written informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CT is editor-in-chief of Alzheimer Research and Therapy. RO is part of the editorial board of Alzheimer\u2019s Research and Therapy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"190"}}